Ascendis Pharma A/S Reports First Quarter 2021 Financial Results
May 27, 2021 16:01 ET
|
Ascendis Pharma
– Pre-launch activities continue in preparation for a potential FDA approval of TransCon™ hGH (lonapegsomatropin) for pediatric growth hormone deficiency; PDUFA date of June 25, 2021 – – 58-week...
Ascendis Pharma A/S Announces First Quarter 2021 Financial Results and Business Update Conference Call on May 27
May 17, 2021 16:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, May 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates...
Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon™ PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan
May 12, 2021 16:28 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, May 12, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates...
Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-Tolerated Safety Profile
May 10, 2021 17:17 ET
|
Ascendis Pharma
– 58 subjects continue in the open-label extension study for TransCon PTH – COPENHAGEN, Denmark, May 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company...
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH at Upcoming Medical Conferences
May 06, 2021 16:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
Ascendis Pharma A/S Announces Participation at the BofA Securities 2021 Virtual Health Care Conference
May 04, 2021 16:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, May 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates...
Ascendis Pharma A/S Announces Presentations for TransCon™ hGH at Upcoming Medical Conferences
April 21, 2021 16:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, April 21, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
Ascendis Pharma A/S Announces Participation at the J.P. Morgan 10th Annual Napa Valley Biotech Forum
March 30, 2021 07:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, March 30, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product...
Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021
March 23, 2021 07:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, March 23, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product...
Ascendis Pharma A/S Announces Participation at Oppenheimer 31st Annual Healthcare Conference
March 15, 2021 07:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, March 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product...